Drug Dependence Clinical Trial
Official title:
Automatic Versus Evaluative Components of Cue Reactivity
Verified date | August 19, 2010 |
Source | National Institutes of Health Clinical Center (CC) |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Background:
- Relapse to drug abuse often happens in the presence of stimuli that are associated with
previous drug use, also known as cues. Drug-taking behavior appears to be partly controlled
by such cues. Some research suggests that cue-induced craving states are responsible for drug
use and relapse, but other research suggests that cues can control drug taking without
conscious craving or even awareness. Researchers are interested in using functional magnetic
resonance imaging (fMRI) to study how individuals respond to drug-related cues and how these
cues affect craving on a conscious or unconscious level.
Objectives:
- To determine how drug-related stimuli (cues) affect thinking, information processing, and
body reactions in current drug users.
Eligibility:
- Individuals between 18 and 50 years of age who are dependent on either tobacco or
crack-cocaine, or are healthy volunteers who are not dependent on either drug.
Design:
- The study will require two sessions, a training session and a testing session, that will
take place within 48 hours of each other. Between the two test sessions, participants
may not consume alcohol, tobacco, or illegal drugs, and must restrict caffeine
consumption.
- During the first session, participants will complete questionnaires about
tobacco/cocaine use and craving, and will be trained on the tasks to be performed in the
MRI scanner.
- During the second session, participants will perform concentration tasks and look at
pictures, some of which will be tobacco/cocaine related. Body reactions such as heart
rate, pupil dilation, and sweating will be measured during this session. Some
participants will have actual MRI scanning, while others will have mock MRI scanning.
- After the MRI session, participants will complete questionnaires about craving and
responses to the scan.
Status | Completed |
Enrollment | 320 |
Est. completion date | August 19, 2010 |
Est. primary completion date | |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 50 Years |
Eligibility |
- INCLUSION CRITERIA: Smokers: Regular smoking of greater than or equal to 20 cigarettes other than ultra-low nicotine cigarettes per day for at least two years. Experienced withdrawal signs after not smoking for several hours. Score on the Fagerstrom Test for Nicotine Dependence greater than or equal to 3. No intention to quit or reduce tobacco use, and no treatment for tobacco dependence currently or during the previous 3 months. No history of abuse of or dependence to any other drug. Age at least 18 and not older than 50 years. Controls: Smoked less than 5 cigarettes during lifetime No history of abuse of or dependence to any drug, including alcohol. Age at least 18 and not older than 50 years. Cocaine abusers: Reported regular crack-cocaine use for at least six months. Meeting DSM-IV criteria for cocaine dependence. No intention to quit or reduce cocaine use, and no treatment for cocaine dependence currently or during the previous 3 months. No dependence on any other drug except nicotine. Recreational use of other drugs of abuse without meeting dependence criteria is not an exclusion criterion. Age at least 18 and not older than 50 years. Controls: No history of dependence on any drug except nicotine. Age at least 18 and not older than 50 years. EXCLUSION CRITERIA: All subject groups Female subjects: pregnancy (a urine pregnancy test will be performed before each MRI experimental session). Presence of metal objects in the body (e.g. some artificial joints, bone pins, surgical clips, skull plate, dental braces) or implanted electronic devices (e.g. cardiac pacemaker, neurostimulator) Claustrophobia. For experiments involving MRI, left-handed or ambidextrous as determined by the Edinburgh Handedness Inventory. Cardiovascular or cerebrovascular diseases. Major psychiatric disorders including mood, anxiety or psychotic disorders. History of or current neurological illnesses including seizure disorders, migraine, multiple sclerosis, movement disorders, head trauma, CVA or CNS tumor. Gross structural brain abnormalities as revealed by T1 weighted images. Use of medication that may affect the CNS at the time of scanning (e.g. b-blocker or analgesics). Learning disability, amnesia or other conditions that impede memory and attention. IQ less than 85. HIV-positivity. |
Country | Name | City | State |
---|---|---|---|
United States | National Institute on Drug Abuse, Biomedical Research Center (BRC) | Baltimore | Maryland |
Lead Sponsor | Collaborator |
---|---|
National Institute on Drug Abuse (NIDA) |
United States,
Abrams DB, Monti PM, Carey KB, Pinto RP, Jacobus SI. Reactivity to smoking cues and relapse: two studies of discriminant validity. Behav Res Ther. 1988;26(3):225-33. — View Citation
Bagby RM, Parker JD, Taylor GJ. The twenty-item Toronto Alexithymia Scale--I. Item selection and cross-validation of the factor structure. J Psychosom Res. 1994 Jan;38(1):23-32. — View Citation
Baker TB, Morse E, Sherman JE. The motivation to use drugs: a psychobiological analysis of urges. Nebr Symp Motiv. 1986;34:257-323. — View Citation
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02564341 -
Targeting Effective Analgesia in Clinics for HIV - Intervention
|
N/A | |
Completed |
NCT02224508 -
Evaluation of a Health Plan Initiative to Mitigate Chronic Opioid Therapy Risks
|
N/A | |
Completed |
NCT00593463 -
Drug Discrimination in Methadone-Maintained Humans Study 1
|
Phase 1 | |
Completed |
NCT03678051 -
CBT4CBT for Women in Residential Treatment for Substance Use Disorders
|
N/A | |
Recruiting |
NCT04003948 -
Preliminary Efficacy and Safety of Ibogaine in the Treatment of Methadone Detoxification
|
Phase 2 | |
Withdrawn |
NCT05440721 -
Clinical Trial of an Innovative Digital Therapeutic for Smoking Cessation With Biochemical Verification
|
N/A | |
Completed |
NCT03694327 -
Innovative Digital Therapeutic for Smoking Cessation
|
N/A | |
Completed |
NCT01449981 -
Development and Testing of Adolescent Twelve-Step Facilitation
|
N/A | |
Completed |
NCT00183118 -
Russia PREVENT (HIV Prevention Partnership in Russian Alcohol Treatment)
|
Phase 1/Phase 2 | |
Completed |
NCT00047866 -
Brain Function in Response to Motivational Stimuli
|
N/A | |
Recruiting |
NCT03333460 -
Transcranial Magnetic Stimulation for Cocaine Addiction
|
N/A | |
Completed |
NCT02124980 -
Automated Recovery Line for Medication Assisted Treatment
|
N/A | |
Terminated |
NCT00975416 -
Oxytocin and Cognitive Behavioral Therapy in Drug Dependence
|
Phase 4 | |
Completed |
NCT00265512 -
LINK: Aftercare Monitoring Project
|
N/A | |
Completed |
NCT00706901 -
Impact of Group Motivational Interviewing and In-Home-Messaging-Devices for Dually Diagnosed Veterans
|
N/A | |
Completed |
NCT02656745 -
Clinical Trial of Smoking Cessation Mobile Phone Program
|
N/A | |
Withdrawn |
NCT00675532 -
Testing a Primary Care Model for the Treatment of Opioid Dependence Using Long-acting Injectable Naltrexone (Vivitrol).
|
N/A | |
Active, not recruiting |
NCT03539575 -
CB1R in Synthetic Psychoactive Cannabinoids
|
N/A | |
Completed |
NCT01246401 -
Naltrexone for Opioid Dependent Released Human Immunodeficiency Virus Positive (HIV+) Criminal Justice Populations
|
Phase 1/Phase 2 | |
Completed |
NCT01096550 -
Intensive Outpatient Versus Outpatient Treatment With Buprenorphine Among African Americans
|
N/A |